Loading…
Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction
Background and Aim Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular re...
Saved in:
| Published in: | Cardiovascular drugs and therapy 2024-04, Vol.38 (2), p.327-333 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3 |
| container_end_page | 333 |
| container_issue | 2 |
| container_start_page | 327 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 38 |
| creator | Yılmaz, Emre Aydın, Ertan Çamcı, Sencer Kurt, Devrim Aydın, Ercan |
| description | Background and Aim
Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF).
Methods
51 patients with HFrEF who had symptoms New York Heart Association (NYHA) class II–IV despite optimal medical treatment and were added SGLT2 inhibitors to their treatment were included in the study. Electrocardiography (ECG) and laboratory results obtained before the treatment and at the first-month follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios were measured and defined as VRM.
Results
A significant decrease was observed in HR, QT, QTc intervals, and QTd compared to pre-treatment. While the mean Tp-e interval was 101.5 ± 11.7 ms before treatment, it decreased to 93.1 ± 12.7 ms after treatment (
p
|
| doi_str_mv | 10.1007/s10557-022-07396-y |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2733205193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2733205193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3</originalsourceid><addsrcrecordid>eNp9kU1vEzEQhi1UREPLH-gBWeqFi8Ef8Xp9RFHSVipCAsrV8u6OW4fNOvhDVfgJ_GqcpoDUQ08z0jzvO6N5ETpj9D2jVH1IjEqpCOWcUCV0Q3Yv0IxJJYjic3aEZlRzSgSnzTF6ndKaVpHW7St0LBox57LhM_R76Rz0GQeHv4bBlw25GEsfEuBFIDnaKW1DzBAJx1fTne98DjHhMOHvMOXo-zLaiL_ANtTqf9ns6-iTjT-gUn7Cl2BjxivrxxIB3_t8V-Gh9DDg5bru3eOraB-aU_TS2THBm8d6gm5Wy2-LS3L9-eJq8fGa9ELJTFijOqcaQZlzVDBqQXPddrIdpO46Bkoq0NCrOecD7-wgtGqgPkS0Leg5d-IEvTv4bmP4WSBls_Gph3G0E4SSDFei_kwyLSp6_gRdhxKnep3heo_JlrWV4geqjyGlCM5so9_YuDOMmn1S5pCUqUmZh6TMrorePlqXbgPDP8nfaCogDkCqo-kW4v_dz9j-Aawjn-o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2973325818</pqid></control><display><type>article</type><title>Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction</title><source>Springer Nature</source><creator>Yılmaz, Emre ; Aydın, Ertan ; Çamcı, Sencer ; Kurt, Devrim ; Aydın, Ercan</creator><creatorcontrib>Yılmaz, Emre ; Aydın, Ertan ; Çamcı, Sencer ; Kurt, Devrim ; Aydın, Ercan</creatorcontrib><description>Background and Aim
Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF).
Methods
51 patients with HFrEF who had symptoms New York Heart Association (NYHA) class II–IV despite optimal medical treatment and were added SGLT2 inhibitors to their treatment were included in the study. Electrocardiography (ECG) and laboratory results obtained before the treatment and at the first-month follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios were measured and defined as VRM.
Results
A significant decrease was observed in HR, QT, QTc intervals, and QTd compared to pre-treatment. While the mean Tp-e interval was 101.5 ± 11.7 ms before treatment, it decreased to 93.1 ± 12.7 ms after treatment (
p
< 0.001). There was a significant decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after treatment [2859 ± 681vs.1266 ± 763, respectively (
p
< 0.001)] and QTd, Tp-e interval, and Tp-e/QTc ratio was positively correlated with the change in NT-proBNP level.
Conclusions
The addition of SGLT2 inhibitors to optimal medical therapy in HFrEF patients positively changes VRM (QT, QTc, QTd, Tp-e, and Tp-e/QTc).</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-022-07396-y</identifier><identifier>PMID: 36342562</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Brain natriuretic peptide ; Cardiology ; Cardiovascular diseases ; Congestive heart failure ; Dispersion ; Ejection fraction ; EKG ; Electrocardiography ; Glucose ; Glucose transporter ; Health risks ; Health services ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - drug therapy ; Humans ; Inhibitors ; Medical treatment ; Medicine ; Medicine & Public Health ; Orignal Article ; Patients ; Sodium ; Sodium-Glucose Transporter 2 Inhibitors - pharmacology ; Stroke Volume ; Symporters ; Ventricle</subject><ispartof>Cardiovascular drugs and therapy, 2024-04, Vol.38 (2), p.327-333</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3</citedby><cites>FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3</cites><orcidid>0000-0003-4230-3248 ; 0000-0002-1656-3778 ; 0000-0001-8743-3762 ; 0000-0003-2152-0470 ; 0000-0002-7280-5137</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36342562$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yılmaz, Emre</creatorcontrib><creatorcontrib>Aydın, Ertan</creatorcontrib><creatorcontrib>Çamcı, Sencer</creatorcontrib><creatorcontrib>Kurt, Devrim</creatorcontrib><creatorcontrib>Aydın, Ercan</creatorcontrib><title>Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Background and Aim
Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF).
Methods
51 patients with HFrEF who had symptoms New York Heart Association (NYHA) class II–IV despite optimal medical treatment and were added SGLT2 inhibitors to their treatment were included in the study. Electrocardiography (ECG) and laboratory results obtained before the treatment and at the first-month follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios were measured and defined as VRM.
Results
A significant decrease was observed in HR, QT, QTc intervals, and QTd compared to pre-treatment. While the mean Tp-e interval was 101.5 ± 11.7 ms before treatment, it decreased to 93.1 ± 12.7 ms after treatment (
p
< 0.001). There was a significant decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after treatment [2859 ± 681vs.1266 ± 763, respectively (
p
< 0.001)] and QTd, Tp-e interval, and Tp-e/QTc ratio was positively correlated with the change in NT-proBNP level.
Conclusions
The addition of SGLT2 inhibitors to optimal medical therapy in HFrEF patients positively changes VRM (QT, QTc, QTd, Tp-e, and Tp-e/QTc).</description><subject>Brain natriuretic peptide</subject><subject>Cardiology</subject><subject>Cardiovascular diseases</subject><subject>Congestive heart failure</subject><subject>Dispersion</subject><subject>Ejection fraction</subject><subject>EKG</subject><subject>Electrocardiography</subject><subject>Glucose</subject><subject>Glucose transporter</subject><subject>Health risks</subject><subject>Health services</subject><subject>Heart failure</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - drug therapy</subject><subject>Humans</subject><subject>Inhibitors</subject><subject>Medical treatment</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Orignal Article</subject><subject>Patients</subject><subject>Sodium</subject><subject>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</subject><subject>Stroke Volume</subject><subject>Symporters</subject><subject>Ventricle</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1vEzEQhi1UREPLH-gBWeqFi8Ef8Xp9RFHSVipCAsrV8u6OW4fNOvhDVfgJ_GqcpoDUQ08z0jzvO6N5ETpj9D2jVH1IjEqpCOWcUCV0Q3Yv0IxJJYjic3aEZlRzSgSnzTF6ndKaVpHW7St0LBox57LhM_R76Rz0GQeHv4bBlw25GEsfEuBFIDnaKW1DzBAJx1fTne98DjHhMOHvMOXo-zLaiL_ANtTqf9ns6-iTjT-gUn7Cl2BjxivrxxIB3_t8V-Gh9DDg5bru3eOraB-aU_TS2THBm8d6gm5Wy2-LS3L9-eJq8fGa9ELJTFijOqcaQZlzVDBqQXPddrIdpO46Bkoq0NCrOecD7-wgtGqgPkS0Leg5d-IEvTv4bmP4WSBls_Gph3G0E4SSDFei_kwyLSp6_gRdhxKnep3heo_JlrWV4geqjyGlCM5so9_YuDOMmn1S5pCUqUmZh6TMrorePlqXbgPDP8nfaCogDkCqo-kW4v_dz9j-Aawjn-o</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Yılmaz, Emre</creator><creator>Aydın, Ertan</creator><creator>Çamcı, Sencer</creator><creator>Kurt, Devrim</creator><creator>Aydın, Ercan</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4230-3248</orcidid><orcidid>https://orcid.org/0000-0002-1656-3778</orcidid><orcidid>https://orcid.org/0000-0001-8743-3762</orcidid><orcidid>https://orcid.org/0000-0003-2152-0470</orcidid><orcidid>https://orcid.org/0000-0002-7280-5137</orcidid></search><sort><creationdate>20240401</creationdate><title>Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction</title><author>Yılmaz, Emre ; Aydın, Ertan ; Çamcı, Sencer ; Kurt, Devrim ; Aydın, Ercan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Brain natriuretic peptide</topic><topic>Cardiology</topic><topic>Cardiovascular diseases</topic><topic>Congestive heart failure</topic><topic>Dispersion</topic><topic>Ejection fraction</topic><topic>EKG</topic><topic>Electrocardiography</topic><topic>Glucose</topic><topic>Glucose transporter</topic><topic>Health risks</topic><topic>Health services</topic><topic>Heart failure</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - drug therapy</topic><topic>Humans</topic><topic>Inhibitors</topic><topic>Medical treatment</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Orignal Article</topic><topic>Patients</topic><topic>Sodium</topic><topic>Sodium-Glucose Transporter 2 Inhibitors - pharmacology</topic><topic>Stroke Volume</topic><topic>Symporters</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yılmaz, Emre</creatorcontrib><creatorcontrib>Aydın, Ertan</creatorcontrib><creatorcontrib>Çamcı, Sencer</creatorcontrib><creatorcontrib>Kurt, Devrim</creatorcontrib><creatorcontrib>Aydın, Ercan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yılmaz, Emre</au><au>Aydın, Ertan</au><au>Çamcı, Sencer</au><au>Kurt, Devrim</au><au>Aydın, Ercan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>38</volume><issue>2</issue><spage>327</spage><epage>333</epage><pages>327-333</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><abstract>Background and Aim
Sodium-glucose co-transporter-2 (SGLT2) inhibitors added to optimal medical therapy have been shown to reduce the risk of cardiovascular death and recurrent heart failure (HF) hospitalization in HF patients. We aimed to evaluate the effect of SGLT2 inhibitors on the ventricular repolarization markers (VRM) in patients with HF with reduced ejection fraction (HFrEF).
Methods
51 patients with HFrEF who had symptoms New York Heart Association (NYHA) class II–IV despite optimal medical treatment and were added SGLT2 inhibitors to their treatment were included in the study. Electrocardiography (ECG) and laboratory results obtained before the treatment and at the first-month follow-up visit were compared. QT, QTc (corrected by Bazett formula), QT dispersion (QTd), QTc dispersion (QTc-d), Tpeak to Tend (Tp-e) interval, Tp-e/QT, and Tp-e/QTc ratios were measured and defined as VRM.
Results
A significant decrease was observed in HR, QT, QTc intervals, and QTd compared to pre-treatment. While the mean Tp-e interval was 101.5 ± 11.7 ms before treatment, it decreased to 93.1 ± 12.7 ms after treatment (
p
< 0.001). There was a significant decrease in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after treatment [2859 ± 681vs.1266 ± 763, respectively (
p
< 0.001)] and QTd, Tp-e interval, and Tp-e/QTc ratio was positively correlated with the change in NT-proBNP level.
Conclusions
The addition of SGLT2 inhibitors to optimal medical therapy in HFrEF patients positively changes VRM (QT, QTc, QTd, Tp-e, and Tp-e/QTc).</abstract><cop>New York</cop><pub>Springer US</pub><pmid>36342562</pmid><doi>10.1007/s10557-022-07396-y</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-4230-3248</orcidid><orcidid>https://orcid.org/0000-0002-1656-3778</orcidid><orcidid>https://orcid.org/0000-0001-8743-3762</orcidid><orcidid>https://orcid.org/0000-0003-2152-0470</orcidid><orcidid>https://orcid.org/0000-0002-7280-5137</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2024-04, Vol.38 (2), p.327-333 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2733205193 |
| source | Springer Nature |
| subjects | Brain natriuretic peptide Cardiology Cardiovascular diseases Congestive heart failure Dispersion Ejection fraction EKG Electrocardiography Glucose Glucose transporter Health risks Health services Heart failure Heart Failure - diagnosis Heart Failure - drug therapy Humans Inhibitors Medical treatment Medicine Medicine & Public Health Orignal Article Patients Sodium Sodium-Glucose Transporter 2 Inhibitors - pharmacology Stroke Volume Symporters Ventricle |
| title | Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Ventricular Repolarization Markers in Heart Failure with Reduced Ejection Fraction |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A12%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Sodium-Glucose%20Co-transporter-2%20Inhibitors%20on%20Ventricular%20Repolarization%20Markers%20in%20Heart%20Failure%20with%20Reduced%20Ejection%20Fraction&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Y%C4%B1lmaz,%20Emre&rft.date=2024-04-01&rft.volume=38&rft.issue=2&rft.spage=327&rft.epage=333&rft.pages=327-333&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/s10557-022-07396-y&rft_dat=%3Cproquest_cross%3E2733205193%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-167bf76301ff0310ae9298b58d59bb1e757e9ec7422d2bad3976e724388e942f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2973325818&rft_id=info:pmid/36342562&rfr_iscdi=true |